BCRX BioCryst Pharmaceuticals Inc
Company Analysis
Latest News
🔴 BioCryst Pharmaceuticals is trading 8% down today amid broad market and biotech selling
BioCryst Pharmaceuticals is trading at $7.58, down 8.01%, as broad equity and biotech selling weighs on growth stocks. - During the November 5, 2026 session,...
🔴 BioCryst Pharmaceuticals is trading 5% down today as licensing and international orders drove revenue outlook
BioCryst Pharmaceuticals is trading 5.31% lower at $8.12 after Q3 earnings and revenue beats; licensing revenue and international RAPIVAB orders drove the...
BioCryst Pharmaceuticals' third quarter 2026 revenue beat estimates and total FY 2026 guidance was raised
BioCryst reported third quarter 2026 results that exceeded top and bottom-line expectations, characterized by robust ORLADEYO demand and an improved expense...
BioCryst Pharmaceuticals Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
BioCryst Pharmaceuticals is projected to report Q3 2026 revenue of $165.68 million and earnings per share of $0.10, while the current stock price of $8.47...
BioCryst Wins FDA Approval for ORLADEYO Pellets for HAE Patients 12+
The U.S. Food and Drug Administration (FDA) approved BioCryst Pharmaceuticals’ supplemental New Drug Application for the oral pellet formulation of once-daily...
🔴 BioCryst Pharmaceuticals is trading 9.0% down in pre-market — no clear catalyst identified
BioCryst Pharmaceuticals is trading 9.0% down at $7.30 in pre-market, with no specific catalyst identified. - No clear company-specific announcement...
🟢 BioCryst Pharmaceuticals is trading 8.07% up in pre-market with no clear catalyst identified
BioCryst Pharmaceuticals is trading 8.07% higher in pre-market at $8.70, with no specific catalyst identified for the move. - The price is compared with the...
🟢 BioCryst Pharmaceuticals is trading 4.58% up in after-hours trading — with no clear catalyst identified
BioCryst Pharmaceuticals is trading at $8.44, up 4.58% in after-hours trading, with no clear company-specific catalyst identified. - No confirmed BioCryst...
🔴 BioCryst Pharmaceuticals is trading 10.74% down in pre-market — reason remains unclear
BioCryst Pharmaceuticals is trading at $7.40, down 10.74% in pre-market, with the reason for the decline unclear. - No clear company-specific announcement...
🟢 BioCryst Pharmaceuticals is trading 4.28% up on October 7, 2026 — no clear catalyst identified
BioCryst Pharmaceuticals is trading at $8.29, up 4.28%, with the reason for the October 7 gain unclear. - The seven-member scientific advisory board was...
🟢 BioCryst Pharmaceuticals is trading 9.4% up in pre-market; no confirmed catalyst
BioCryst Pharmaceuticals is trading at $8.70, up 9.43% in pre-market, with no confirmed company-specific catalyst for the October 7 move. - The price is...
🟢 BioCryst Pharmaceuticals is trading 4.8% up in pre-market with catalyst attribution unconfirmed
BioCryst Pharmaceuticals is trading 4.8% higher in pre-market at $8.49 on October 6, versus the October 5 close of $8.10; available sources do not confirm a...
🔴 BioCryst Pharmaceuticals is trading 6.5% down today after Pharvaris’s positive late-stage hereditary-angioedema results
BioCryst Pharmaceuticals is trading 6.5% down at $8.23 after continued pressure from Pharvaris’s positive late-stage hereditary-angioedema trial results, which...
🔴 BioCryst Pharmaceuticals is trading 7.63% down today
BioCryst Pharmaceuticals is trading at $9.20, -7.63%, with no clear company-specific catalyst identified for September 8, 2026. - The latest announcement was...
🔴 BioCryst Pharmaceuticals is trading 4.2% down in pre-market with no clear company-specific catalyst identified
BioCryst Pharmaceuticals is trading 4.2% down now at $9.54 after no clear company-specific catalyst was identified for September 8, 2026. - The latest company...
🔴 BioCryst Pharmaceuticals is trading 4.26% down in pre-market
BioCryst Pharmaceuticals is trading 4.26% down at $9.41 after no clear negative company-specific catalyst was identified for August 26, 2026. - The latest...
🔴 BioCryst Pharmaceuticals is trading 4.37% down today amid broader biotech profit-taking
BioCryst Pharmaceuticals is trading at $9.63, with a -4.37% move on August 20, 2026, amid biotech profit-taking after the previous session’s Moderna-driven...
🟢 BioCryst Pharmaceuticals rises 4.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 BioCryst Pharmaceuticals is trading 5.6% up today in pre-market following stronger-than-expected Q2 results
BioCryst Pharmaceuticals is trading 5.63% up now at $10.50, with continued buying potentially supported by its August 5 earnings report. - The report showed...
🔴 BioCryst Pharmaceuticals is trading 4.15% down today with no clear catalyst identified
BioCryst Pharmaceuticals is trading 4.15% down at $10.15, with no clear company-specific announcement or analyst action identified for August 13, 2026. - The...